YMTracker DRIPCalc v2 Launch sale

NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

NVAX | NASDAQ

$10.78 -$0.03 | -0.28%

SIGNAL:

Signal available — unlock to view

|2026-09-29 |F&G 75 |RSI 65.8

Add to favoritesFavorite

Company Overview:

Market Cap: $1.78B

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $6.20 - $11.97

10 Year NVAX Performance Metrics:

Total Return (with DRIP): -74.1% (-12.63% CAGR)

Total Return (no DRIP): -74.1% (-12.63% CAGR)

Share Price: -74.1% (-12.63% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $2,591

Total Return $ (with DRIP): -$7,409

NVAX Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

NVAX Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

NVAX Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

NVAX - Revenue

NVAX Revenue CAGR:1Y: -76.30%2Y: -63.06%5Y: -28.24%10Y: 36.61%

NVAX - Earnings Per Share (EPS)

NVAX EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - Net Income

🔓 See the full chart40% off right now · 7-day free trial

NVAX Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

NVAX EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

NVAX Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

NVAX Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

NVAX Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

NVAX Gross Profit CAGR:1Y: -81.13%2Y: -66.09%5Y: -32.28%10Y: 32.71%

NVAX - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

NVAX Shares Outstanding CAGR:1Y: -7.13%2Y: -0.39%5Y: 17.30%10Y: 28.38%

NVAX - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

NVAX Share Buybacks CAGR:1Y: 54.27%2Y: 0.00%5Y: 25.21%10Y: 0.00%

NVAX - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

NVAX Stock-Based Comp CAGR:1Y: -12.21%2Y: -24.26%5Y: -31.37%10Y: 4.40%

NVAX - Expenses

🔓 See the full chart40% off right now · 7-day free trial

NVAX Expenses CAGR:1Y: 414.17%2Y: -36.25%5Y: -39.09%10Y: -13.68%

NVAX - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

NVAX - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

NVAX - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

NVAX - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

NVAX - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

NVAX - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

NVAX - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

NVAX Revenue CAGR:1Y: -76.30%2Y: -63.06%5Y: -28.24%10Y: 36.61%

NVAX - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

NVAX Revenue CAGR:1Y: -76.30%2Y: -63.06%5Y: -28.24%10Y: 36.61%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

NVAX - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

NVAX Actual Revenue CAGR:1Y: -76.30%2Y: -63.06%5Y: -28.24%10Y: 36.61%

NVAX - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

NVAX Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

NVAX Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

NVAX Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

NVAX - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

NVAX Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

NVAX Gross Profit Margin CAGR:1Y: -20.39%2Y: -8.21%5Y: -5.62%10Y: -2.85%

NVAX - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

NVAX Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

NVAX Price To Sales Ratio CAGR:1Y: 540.87%2Y: 145.24%5Y: -12.33%10Y: -28.53%

NVAX - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

NVAX Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NVAX - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

NVAX Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for NVAX

Based on past 10-year performance, here are NVAX growth metrics:

Share price CAGR of -12.63%
Dividend CAGR of +0%

Using NVAX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	NVAX (DRIP)	NVAX - No DRIP
Current Price	$10.78	$10.78
Start Shares	927.64	927.64
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	927.64	927.64
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$2.79	$10.78
Total Dividends	$0	$0
Final Value	$2,591	$10,000

Estimated Future Value + Dividends - NVAX

NOTE: Above numbers are our estimate based on NVAX's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Company Info

Novavax, Inc. (NVAX) had its IPO on 1995-12-05, and is traded on NASDAQ stock exchange.

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

NVAX website: https://www.novavax.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Loading signals…

DCF Model — NVAX

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $10.78

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own NVAX? See every dividend it's paid you

Add your NVAX shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every NVAX dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

Add NVAX free →

Free plan · up to 5 holdings